First American Trust FSB acquired a new stake in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 17,498 shares of the medical research company’s stock, valued at approximately $3,624,000.
Other hedge funds and other institutional investors have also modified their holdings of the company. Johnson Financial Group Inc. boosted its holdings in Thermo Fisher Scientific by 2,608.7% during the first quarter. Johnson Financial Group Inc. now owns 623 shares of the medical research company’s stock worth $129,000 after purchasing an additional 600 shares during the last quarter. Virtue Capital Management LLC purchased a new position in Thermo Fisher Scientific during the fourth quarter worth about $127,000. Premia Global Advisors LLC purchased a new position in Thermo Fisher Scientific during the fourth quarter worth about $131,000. Private Capital Group LLC boosted its holdings in Thermo Fisher Scientific by 57.3% during the first quarter. Private Capital Group LLC now owns 865 shares of the medical research company’s stock worth $179,000 after purchasing an additional 315 shares during the last quarter. Finally, Jacobi Capital Management LLC boosted its holdings in Thermo Fisher Scientific by 45.5% during the first quarter. Jacobi Capital Management LLC now owns 908 shares of the medical research company’s stock worth $184,000 after purchasing an additional 284 shares during the last quarter. Hedge funds and other institutional investors own 85.76% of the company’s stock.
Get Thermo Fisher Scientific alerts:Thermo Fisher Scientific traded down $0.12, hitting $207.23, during mid-day trading on Friday, MarketBeat Ratings reports. 27,876 shares of the stock traded hands, compared to its average volume of 1,223,739. The stock has a market cap of $82.83 billion, a P/E ratio of 21.85, a P/E/G ratio of 1.51 and a beta of 1.10. Thermo Fisher Scientific Inc. has a 12-month low of $170.07 and a 12-month high of $226.44. The company has a current ratio of 1.36, a quick ratio of 0.95 and a debt-to-equity ratio of 0.69.
Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, April 25th. The medical research company reported $2.50 EPS for the quarter, beating the consensus estimate of $2.42 by $0.08. The company had revenue of $5.85 billion during the quarter, compared to analysts’ expectations of $5.62 billion. Thermo Fisher Scientific had a net margin of 10.24% and a return on equity of 16.09%. Thermo Fisher Scientific’s revenue for the quarter was up 22.8% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.08 earnings per share. equities analysts forecast that Thermo Fisher Scientific Inc. will post 10.9 earnings per share for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Monday, July 16th. Shareholders of record on Friday, June 15th will be paid a $0.17 dividend. The ex-dividend date is Thursday, June 14th. This represents a $0.68 dividend on an annualized basis and a yield of 0.33%. Thermo Fisher Scientific’s dividend payout ratio is presently 7.17%.
In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 45,000 shares of the business’s stock in a transaction that occurred on Friday, June 15th. The shares were sold at an average price of $214.80, for a total value of $9,666,000.00. Following the completion of the transaction, the chief executive officer now owns 315,122 shares of the company’s stock, valued at approximately $67,688,205.60. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Marc N. Casper sold 50,000 shares of the business’s stock in a transaction that occurred on Wednesday, June 13th. The stock was sold at an average price of $217.71, for a total transaction of $10,885,500.00. Following the completion of the transaction, the chief executive officer now directly owns 272,122 shares of the company’s stock, valued at approximately $59,243,680.62. The disclosure for this sale can be found here. In the last three months, insiders sold 97,706 shares of company stock valued at $21,125,673. Corporate insiders own 0.49% of the company’s stock.
Several research analysts recently weighed in on the stock. Zacks Investment Research cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Monday, March 26th. Morgan Stanley lifted their price objective on shares of Thermo Fisher Scientific from $216.00 to $230.00 and gave the stock an “overweight” rating in a research report on Thursday, April 26th. Finally, ValuEngine lowered shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research report on Wednesday, June 20th. Two analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $224.38.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
No comments:
Post a Comment